This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

The Clinical Trials Industry’s Weekly News Update

CCR buys Genpro citing international presence and AI-based approach

Share this article

North Carolina-based CRO Catalyst Clinical Research (CCR) has acquired Massachusetts counterpart Genpro Research citing its AI technology as a key motivation.

The deal – financial terms of which were not provided – will add Genpro’s capabilities in biometrics, medical writing, RWE, AI-enabled automation product development and operations in the US, India, and Ireland to CCR’s business.

In total, the acquisition will add more than 120 Genpro staff in India with experience in biometrics and medical writing to CCR’s team.

Catalyst CEO Nick Dyer cited Genpro’s technology based and global reach as prompts for the takeover.
“We share the opportunity to expand our global footprint, broaden and deepen our services, and to use the artificial intelligence (AI) platform to create value for ourselves and customers in a range of labor-intensive document creation processes.

“In addition,” Dryer said, “our approach to prioritizing culture and treating our teams like family are similar and will act as a critical foundation for our combined company as we move forward.”

This was echoed by Melissa Church, senior vice president, strategy at Catalyst, expressed the strategic significance of the acquisition.

“Catalyst is extremely intentional in its acquisition approach, ensuring we choose organizations that are additive to our capabilities and match well with our people-first culture.

“In Genpro we are gaining a very talented team delivering function specific biometrics and medical writing services which fits squarely in our strategic growth plan."

Genpro CEO Sachin Marulkar predicted the combined firms would be able to reach a wider client base, explaining “By joining Catalyst, we will continue to expand our biometrics, scientific reporting, and technology offerings, have access to more opportunities globally, and provide our clients with additional products and services.

“We are excited to utilize the synergies in advancing our AI/ML technology platform to create beneficial new tools and improve the efficiency of clinical research.”


Share this article

Sign up for Clinical Insider email updates